Calcium/calmodulin-dependent protein kinase II (CaMKII) is a pivotal signaling molecule in both the brain and the heart. In this issue of Cell, Erickson et al. (2008) demonstrate a mechanism for CaMKII activation by reactive oxygen species that provides a direct link between kinase activation and cardiac dysfunction. localization results in the production of ROS and the activation of kinases and transcriptional responses that can lead to apoptosis or cardiac hypertrophy.
The regulation of calcium/calmodulindependent protein kinase II (CaMKII) is of intense interest to neuroscientists due to its role in neuronal plasticity. However, CaMKII also has important functions in other tissues such as the heart. In this issue of Cell, Erickson et al. (2008) add a new piece to the puzzle of CaMKII regulation with their demonstration that reactive oxygen species (ROS) involve activation of CaMKII and cardiac pathology. These findings may have important implications for our understanding of disease mechanisms in both the heart and nervous system.
In the brain, the coupling of cell excitation and Ca 2+ influx to the calmodulin-(Ca 2+ /CaM) triggered activation of CaM-KII is a critical signaling mechanism. The cardinal feature of CaMKII, which is believed to underlie its role in neuronal plasticity, is its ability to remain active independent of Ca 2+ /CaM binding after its initial activation (for review, see Griffith, 2004) . During CaMKII activation, binding of Ca 2+ /CaM to the regulatory domain of CaMKII disrupts the interaction between the autoinhibitory sequences and the N-terminal catalytic domain to allow for substrate phosphorylation. Activation also catalyzes autophosphorylation within the autoinhibitory domain at threonine 287 (T287 for β, γ, δ isozymes; T286 for αCaMKII). It is this threonine phosphorylation that gives CaMKII its ability to remain active even after dissociation of Ca 2+ /CaM, as the modification prevents the reassociation of the CaMKII autoinhibitory domain even in the absence of Ca 2+ / CaM. This property of the kinase allows it to remain active for a prolonged period of time after the Ca 2+ concentration in the cytoplasm has returned to basal levels, thereby allowing neurons to retain a "memory" of the excitation. The CaM-binding domain of the kinase can also undergo autophosphorylation at T306 and T307. Phosphorylation at these sites blocks binding of CaM and provides a mechanism for inhibiting kinase activation (Lu et al., 2003) .
Neurons are of course not the only excitable cells in the body-heart cells are also excitable. In the heart, CaM-KII is known to be critically involved in coupling excitation and contraction of muscle through regulation of voltagegated Na + , K + , and Ca 2+ channels as well as a variety of Ca 2+ handling proteins (Maier and Bers, 2007) . Constitutively active CaMKII is elevated in a number of pathological conditions of the heart and has a pivotal role in mediating cardiac remodeling induced by hyperactivation of β-adrenergic receptors (Zhang et al., 2005) . Intriguingly, CaMKII is also activated by the pro-oxidant cellular environment produced in many other forms of cardiac dysfunction. Shear stress, volume overload, and reperfusion after anoxia all induce the production of ROS through activation of NADPH oxidase. In addition, a diverse collection of agents, including angiotensin II, induce translocation of the NADPH oxidase subunit p47 to the cell membrane. This change in p47 localization results in the production of ROS and the activation of kinases and transcriptional responses that can lead to apoptosis or cardiac hypertrophy.
Erickson and colleagues set out to determine how ROS activate CaMKII by first examining the effects of a powerful ROS, hydrogen peroxide (H 2 O 2 ), on purified δCaMKII. They found that in the presence of Ca 2+ /CaM, H 2 O 2 treatment caused CaMKII to become constitutively active. Importantly, this activation was entirely independent of phosphorylation at T287, given that it occurred even when the threonine was mutated to alanine (T287A). Reasoning that this activation had to involve the well-characterized regulatory domain of CaMKII, the authors used protein chemistry to look for oxidative modifications of cysteine and methionine residues. They found that oxidation of either methionine 281 or methionine 282 (M281 or M282) could activate the kinase, whereas oxidation of cysteines or other methionines in this domain had no effect. These findings suggest that binding of Ca 2+ /CaM induces a conformational change that opens up the regulatory domain of the kinase and makes these methionines available for modification. The requirement for initial Ca 2+ /CaM binding is also a feature of T287 phosphorylation, suggesting that the regulatory domain is normally protected by intramolecular interactions in the inactive state (Figure 1 ). Having identified a new mode of residue modification in the regulatory domain, the authors then set out to explore the physiological role of methionine oxidation in CaMKII. Erickson et al. compared the effects of two agents that are known to be involved in cardiac tissue remodeling: the hormone angiotensin II, which increases the generation of ROS, and the β-adrenergic agonist isoproterenol, which increases intracellular Ca 2+ and activates CaMKII. Using an oxidation-specific antibody, they showed that oxidation of M281/282 occurs in vivo in the hearts of angiotensin II-treated mice but not in the hearts of mice treated with isoproterenol. This suggested that the modification is dependent on the presence of ROS. Consistent with this, CaMKII oxidation was blocked by mutation of p47, the NADPH oxidase subunit responsible for increased ROS following angiotensin II treatment. Finally, mutation of MsrA, the enzyme that regenerates methionine from its oxidized form, enhanced oxidation of CaMKII. Though both angiotensin II and isoproterenol stimulate phosphorylation of δCaMKII at T287, angiotensin II-stimulated phosphorylation was blocked by mutation of p47. This suggested that ROS also have effects, possibly mediated by regulation of phosphatases, on the steadystate levels of phosphorylated T287. Both oxidation and phosphorylation of the regulatory domain were blocked in mice expressing AC3I, a peptide inhibitor of CaMKII, supporting the role of initial kinase activation in the generation of these distinct constitutively active species.
The authors go on to establish the clinical relevance of CaMKII activation by oxidation in a very elegant set of experiments. In cultured cardiac myocytes, they showed that following downregulation of endogenous δCaMKII with a short hairpin RNA (shRNA), expression of shRNA-resistant wild-type δCaMKII supported both angiotensin II-and isoproterenol-stimulated apoptosis. In contrast, expression of a mutant kinase in which M281 and M282 are replaced by valines (M281/282V) only supported β-agonist isoproterenol-triggered cell death. The authors coupled these exciting results with additional experiments showing that mice with surgically induced myocardial infarction had increased CaM-KII M281/282 oxidation and that MsrA mutant mice have worse outcomes in terms of cardiac function and mortality. These findings together build a strong case for oxidative modification of CaM-KII as a significant contributor to ROSmediated pathology.
This study, together with previous work from this group (Zhang et al., 2005) , places CaMKII activation at the heart of the pathological mechanisms of both β-adrenergic and ROS-mediated cardiac damage. Both pathways are activated in the context of elevated Ca 2+ levels in the beating heart and can cause autophosphorylation-dependent activation of CaMKII. This study demonstrates that signaling molecules that generate ROS have an additional mechanism for the activation of CaMKII via oxidation. Given that the localization of CaMKII is critical to its specificity (Schulman, 2004) , it will be interesting to see if oxidation-modified CaMKII and phosphorylated CaMKII are differentially localized within the myocyte or whether they act on different sets of effectors. In both cases, inhibiting CaM- Phosphorylation within the CaM-binding domain at T306 or T307 can occur when CaM dissociates from CaMKII phosphorylated on T287 (Patton et al., 1990) or when unphosphorylated CaMKII is in a complex with CASK (at low Ca 2+ concentrations), a MAGUK scaffolding protein (Lu et al., 2003) . This phosphorylation blocks subsequent Ca 2+ /CaM binding and activation of CaMKII. Erickson et al. (2008) show that M281/ M282 can also be modified by oxidation to generate Ca 2+ /CaM-independent activity, suggesting that our definition of the regulatory domain of CaMKII should be expanded to include these residues. KII in the heart may be an appealing therapeutic approach for preventing sudden death following a heart attack. Moreover, ROS-dependent pathology is important in many neurological conditions including Alzheimer's disease (Infanger et al., 2006) and the vascular dysfunction that follows subarachnoid hemorrhage (Zemke et al., 2007) . The ability of CaMKII to be directly stimulated by the generation of ROS may connect this versatile enzyme to a variety of other diseases.
The serine/threonine protein kinase Akt is activated by a wide range of stimuli, such as growth factors and cytokines (Manning and Cantley, 2007) , and has been implicated in many aspects of cellular regulation, including cell survival, growth, proliferation, migration, and metabolism. Likewise, numerous Akt substrates have been identified that mediate these effects (Figure 1 ). Because phosphorylation of specific Akt substrates determines the cellular response, a major question in Akt signaling is how substrate selectivity is achieved. In this issue, Schenck et al. (2008) provide evidence for the role of spatial regulation in Akt signaling. They show that the binding of Akt to the endosomal protein Appl1 contributes to Akt's substrate selectivity and promotes cell survival in zebrafish development.
Human APPL1 (adaptor protein containing PH domain, PTB domain, and leucine zipper) was originally identified as an Akt-interacting protein (Mitsuuchi et al., 1999) . Subsequent studies have established that APPL1 is a direct downstream effector of Rab5 (Miaczynska et al., 2004) , a GTPase involved in endocytosis. In new work using a zebrafish model, Schenck et al. now show that downregulation of Appl1 or Appl2 by antisense morpholinos markedly increases apoptosis in tissues that normally have high levels of expression of Appl1 and Appl2 (Schenck et al., 2008) . A role for Appl2 in cell survival during development is further supported by genetic mutation analyses.
Previous work has shown that activity of mammalian Akt is enhanced by binding to APPL1 in response to various signals. Similarly, Schenck et al. show that activation of Akt by growth factor stimulation is diminished by morpholino knockdown of Appl1 in zebrafish. Based on these and other findings the authors conclude that Appl1 is essential for the prosurvival function of Akt. They then examined the effect of depleting Appl1 on the phosphorylation of two Akt substrates, glycogen synthase kinase 3 (Gsk3) and tuberous sclerosis protein 2 (Tsc2). Surprisingly, inactivation of Appl1 only decreases the phosphorylation of Gsk3 but not Tsc2 (Figure 1 ), suggesting that Appl1 may affect the substrate selectivity of Akt in vivo.
The colocalization of APPL1 with Akt and GSK3, but not TSC2, further supports the notion that Appl1 regulates Akt substrate selectivity (Schenck et al., 2008) . Human APPL1 is localized in multiple cellular compartments, including endosomes (Miaczynska et al., 2004 
